Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (NASDAQ: BMRN) and Premier (NASDAQ: PINC)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin Pharmaceutical (BMRNResearch Report) and Premier (PINCResearch Report).

BioMarin Pharmaceutical (BMRN)

In a report released yesterday, Martin Auster from Credit Suisse maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $128.00. The company’s shares closed last Monday at $107.43, close to its 52-week high of $109.51.

According to TipRanks.com, Auster is a 5-star analyst with an average return of 19.1% and a 61.2% success rate. Auster covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Ultragenyx Pharmaceutical, and Alexion Pharmaceuticals.

BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $119.88, representing a 12.6% upside. In a report issued on May 20, J.P. Morgan also maintained a Buy rating on the stock with a $140.00 price target.

See today’s analyst top recommended stocks >>

Premier (PINC)

Credit Suisse analyst Jailendra Singh maintained a Hold rating on Premier today and set a price target of $37.00. The company’s shares closed last Monday at $34.48.

According to TipRanks.com, Singh is a 4-star analyst with an average return of 15.3% and a 86.7% success rate. Singh covers the Services sector, focusing on stocks such as AmerisourceBergen, Cardinal Health, and Owens & Minor.

Currently, the analyst consensus on Premier is a Moderate Buy with an average price target of $37.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.